New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2013
08:13 EDTTKMRTekmira Pharmaceuticals to expand, advance pipeline of proprietary products
Tekmira Pharmaceuticals announced its key product development, corporate, and partner milestones for 2013. "Tekmira has been at the forefront of the RNAi technology revolution over the last decade, and 2012 proved to be a pivotal year for the RNAi field where Tekmira's LNP technology enabled multiple promising sets of human clinical data. It is Tekmira's deep knowledge and our ability to continuously innovate and improve our LNP technology platform which is driving the RNAi field forward," said Dr. Mark J. Murray, Tekmira's president and CEO. "Building upon this positive momentum, in the year ahead, we will expand and advance Tekmira's pipeline of proprietary products, in order to maximize value for our shareholders. We intend to present results from our Phase I clinical trial with TKM-PLK1, our lead cancer program, and we anticipate it will enter Phase II clinical trials later this year. We will continue to advance our TKM-Ebola product in collaboration with the U.S. Department of Defense's TMT program. And, we expect to nominate and move forward with our next target for development. Looking at our partners, we anticipate results from Alnylam's ALN-TTR02 Phase II trial in mid-2013 and the initiation of a Phase III trial by the end of 2013 and we expect to receive $10M in milestone payments from Alnylam in 2013. In addition, we are entitled to future royalty payments based on sales of Marqibo, which was recently approved by the FDA. With clarity around the intellectual property protecting our LNP technology platform, we are well-positioned to pursue product, platform and strategic partnering deals," added Dr. Murray.
News For TKMR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
13:24 EDTTKMRLiberia, U.S. begin ZMapp ebola trial
In partnership with the Liberian government, the National Institute of Allergy and Infectious Diseases launched a clinical trial to obtain safety and efficacy data on the investigational drug ZMapp as a treatment for Ebola virus disease. The study may be expanded to test ZMapp against other treatments which may also include the following: Tekmira siRNA from Tekmira Pharmaceuticals (TKMR), Favipiravir from Toyama Chemical, BCX4430 from BioCryst (BCRX), and AVI-7537 from Sarepta (SRPT). The trial is expected to conclude in December 2016.
February 26, 2015
11:32 EDTTKMRTekmira to host special shareholder meeting
Subscribe for More Information
05:27 EDTTKMRTekmira announces update to proxy circular on merger with OnCore
Tekmira Pharmaceuticals announced an update to persons who will serve as members of the board of the company upon completion of the company's proposed business combination with OnCore Biopharma, as described in the company's proxy circular regarding the transaction, dated February 4. The board of the combined company upon completion of the merger will consist of Vivek Ramaswamy, who will serve as chairman of the board, Mark Murray, Ph.D., Richard Henriques, Jr., Keith Manchester, Frank Karbe, William T. Symonds, Pharm. D., and Herbert Conrad. Daniel Kisner, M.D., will not serve as a director or vice chairman of the board for the combined company.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use